Register entry
Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC
Data as of · How to read this entry
- Registered sites
- 0
- Active NDC listings
- 18
- Labeller names
- 2
- Live patents
- 0
- Countries
- 0
Catalogue
Drug listings by form and route
1818 active NDC listings: 14 plasma derivative, 2 drug for further processing, 2 vaccine. By marketing category: BLA 16, DRUG FOR FURTHER PROCESSING 2.
| Dosage form | NDCs |
|---|---|
| kit | 14 |
| injection, suspension | 2 |
| liquid | 2 |
| Route | NDCs |
|---|---|
| intramuscular | 2 |
| Labeller name on the listing | NDCs |
|---|---|
| wyeth biopharma division of wyeth pharmaceuticals llc | 16 |
| wyeth pharmaceutical division of wyeth holdings llc | 2 |
Catalogue
Marketed products
18| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| - | Adalimumab | liquid | 58394-051DRUG FOR FURTHER PROCESSING |
| BeneFIX | coagulation factor ix (recombinant) | kit | 58394-633BLA |
| BeneFIX | coagulation factor ix (recombinant) | kit | 58394-634BLA |
| BeneFIX | coagulation factor ix (recombinant) | kit | 58394-635BLA |
| BeneFIX | coagulation factor ix (recombinant) | kit | 58394-636BLA |
| BeneFIX | coagulation factor ix (recombinant) | kit | 58394-637BLA |
| Prevnar 20 | Pneumococcal 20-valent Conjugate Vaccine | injection, suspension, intramuscular | 0005-2000BLA |
| Trumenba | meningococcal group B vaccine | injection, suspension, intramuscular | 0005-0100BLA |
| Xyntha | antihemophilic factor (recombinant) | kit | 58394-012BLA |
| Xyntha | antihemophilic factor (recombinant) | kit | 58394-013BLA |
| Xyntha | antihemophilic factor (recombinant) | kit | 58394-014BLA |
| Xyntha | antihemophilic factor (recombinant) | kit | 58394-015BLA |
| Xyntha | antihemophilic factor (recombinant) | kit | 58394-016BLA |
| Xyntha | antihemophilic factor (recombinant) | kit | 58394-022BLA |
| Xyntha | antihemophilic factor (recombinant) | kit | 58394-023BLA |
| Xyntha | antihemophilic factor (recombinant) | kit | 58394-024BLA |
| Xyntha | antihemophilic factor (recombinant) | kit | 58394-025BLA |
| - | bevacizumab | liquid | 58394-095DRUG FOR FURTHER PROCESSING |
Enquiry
Common questions
- Is Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC FDA approved?
- Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC holds no registered establishment of its own; 18 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC make?
- 18 products are listed under Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC in the openFDA NDC Directory, most often as kit; injection, suspension; liquid. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.